JP7193448B2 - 酢酸グラチラマーを含むデポシステム - Google Patents

酢酸グラチラマーを含むデポシステム Download PDF

Info

Publication number
JP7193448B2
JP7193448B2 JP2019508893A JP2019508893A JP7193448B2 JP 7193448 B2 JP7193448 B2 JP 7193448B2 JP 2019508893 A JP2019508893 A JP 2019508893A JP 2019508893 A JP2019508893 A JP 2019508893A JP 7193448 B2 JP7193448 B2 JP 7193448B2
Authority
JP
Japan
Prior art keywords
depot formulation
glatiramer
depot
patient
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019508893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530648A (ja
JP2019530648A5 (cg-RX-API-DMAC7.html
Inventor
マロム，エフド
キメルマン，ナダブ ブライヒ
ダノン，ウリ
ルブノヴ，シャイ
Original Assignee
マピ ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マピ ファーマ リミテッド filed Critical マピ ファーマ リミテッド
Publication of JP2019530648A publication Critical patent/JP2019530648A/ja
Publication of JP2019530648A5 publication Critical patent/JP2019530648A5/ja
Application granted granted Critical
Publication of JP7193448B2 publication Critical patent/JP7193448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Resins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Chemical Vapour Deposition (AREA)
JP2019508893A 2016-08-31 2017-08-09 酢酸グラチラマーを含むデポシステム Active JP7193448B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662381598P 2016-08-31 2016-08-31
US62/381,598 2016-08-31
PCT/IL2017/050882 WO2018042415A1 (en) 2016-08-31 2017-08-09 Depot systems comprising glatiramer acetate

Publications (3)

Publication Number Publication Date
JP2019530648A JP2019530648A (ja) 2019-10-24
JP2019530648A5 JP2019530648A5 (cg-RX-API-DMAC7.html) 2020-09-17
JP7193448B2 true JP7193448B2 (ja) 2022-12-20

Family

ID=61300274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019508893A Active JP7193448B2 (ja) 2016-08-31 2017-08-09 酢酸グラチラマーを含むデポシステム

Country Status (21)

Country Link
US (1) US12370233B2 (cg-RX-API-DMAC7.html)
EP (2) EP3506921B1 (cg-RX-API-DMAC7.html)
JP (1) JP7193448B2 (cg-RX-API-DMAC7.html)
CN (1) CN109982712A (cg-RX-API-DMAC7.html)
AU (1) AU2017319728B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019003594A2 (cg-RX-API-DMAC7.html)
CA (1) CA3035147A1 (cg-RX-API-DMAC7.html)
DK (1) DK3506921T3 (cg-RX-API-DMAC7.html)
ES (2) ES3023741T3 (cg-RX-API-DMAC7.html)
FI (1) FI3506921T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20250396T1 (cg-RX-API-DMAC7.html)
HU (2) HUE071047T2 (cg-RX-API-DMAC7.html)
IL (2) IL301455B2 (cg-RX-API-DMAC7.html)
LT (1) LT3506921T (cg-RX-API-DMAC7.html)
MX (1) MX2019002284A (cg-RX-API-DMAC7.html)
PL (2) PL4252849T3 (cg-RX-API-DMAC7.html)
PT (1) PT3506921T (cg-RX-API-DMAC7.html)
RS (2) RS66690B1 (cg-RX-API-DMAC7.html)
SI (1) SI3506921T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202300251T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018042415A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11471421B2 (en) 2016-08-28 2022-10-18 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
WO2023170493A1 (en) * 2022-03-07 2023-09-14 Hadidi Naghmeh Drug delivery using a parenteral pharmaceutical composition
EP4493274A1 (en) 2022-03-17 2025-01-22 Mapi Pharma Ltd. Depot systems comprising cariprazine or salts thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516403A (ja) 2010-01-04 2013-05-13 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
WO2018042423A1 (en) 2016-08-28 2018-03-08 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3673317D1 (de) 1985-10-11 1990-09-13 Duphar Int Res Automatische spritze.
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
HU221294B1 (en) 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IT1276690B1 (it) 1995-06-09 1997-11-03 Ira Srl Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema
NZ325561A (en) 1996-01-24 1999-06-29 Us Army Pharmaceutical composition containing an active ingredient and poly(lactide/glycolide) microcapsules which is a burst free controlled release formulation
BRPI9707379B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US20070185032A1 (en) 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6454746B1 (en) 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
JP2002503658A (ja) 1998-02-13 2002-02-05 オートイミューン インク ＣＯＰ−１及びＴｈ−２促進性サイトカインを使用した、多発性硬化症の治療
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
IL140592A0 (en) 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
EP2090583B1 (en) 1998-09-25 2011-07-13 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en) 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
EP1128839A4 (en) 1998-11-12 2002-10-09 Yeda Res & Dev PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
DE60041365D1 (de) 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
US6531130B1 (en) 1999-07-06 2003-03-11 The Board Of Trustees Of The Leland Stanford University Treatment of demyelinating autoimmune disease with ordered peptides
HK1054507B (zh) 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
ATE329608T1 (de) 2000-02-18 2006-07-15 Yeda Res & Dev Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
JP2003535118A (ja) 2000-06-05 2003-11-25 テバ ファーマシューティカル インダストリーズ リミティド 中枢神経系障害の治療におけるグラチラマーアセテート（共重合体１）の使用
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
EP1294390B1 (en) 2000-06-07 2006-01-04 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
WO2008150547A1 (en) 2007-06-04 2008-12-11 The Regents Of The University Of California Pregnancy hormone combination for treatment of autoimmune diseases
US6835711B2 (en) 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy
IL159715A0 (en) 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
NZ532199A (en) 2001-10-03 2008-02-29 Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
US7132438B2 (en) 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives
AU2002365649A1 (en) 2001-11-28 2003-06-17 Immunomedics, Inc. Anti-dota antibody
MXPA04005433A (es) 2001-12-04 2004-10-11 Teva Pharma Proceso para la medicion de la potencia de acetato de glatiramero.
CN102151330B (zh) 2001-12-06 2017-04-12 耶达研究及发展有限公司 治疗运动神经元疾病的疫苗和方法
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
CN1398584A (zh) 2002-07-15 2003-02-26 裴福兴 一种bFGF－PLGA缓释微球及其制备方法和用途
DE10237146A1 (de) 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
AU2003283152A1 (en) 2002-11-13 2004-06-03 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
WO2004047893A1 (de) 2002-11-25 2004-06-10 Tecpharma Licensing Ag Autoinjektor mit rückstellbarer auslösesicherung
EP1583506B1 (en) 2003-01-07 2012-03-07 Yeda Research And Development Co., Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
PT1592384E (pt) 2003-01-21 2013-01-28 Yeda Res & Dev Cop-1 para o tratamento de doenças inflamatórias do intestino
CA2518079A1 (en) 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
HRP20140524T1 (hr) 2003-05-14 2014-12-19 Teva Pharmaceutical Industries Ltd. Kombinacijska terapija glatiramer acetatom i mitoksantronom za lijeäśenje multiple skleroze
KR101137785B1 (ko) 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
CA2533649A1 (en) 2003-07-31 2005-02-03 Yeda Research And Development Co. Ltd. Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
EA200600877A1 (ru) 2003-10-31 2006-12-29 Тева Фармасьютикал Индастриз, Лтд. Наночастицы для доставки лекарств
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
EP2633853A1 (en) 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Long-term delivery formulations and methods of use thereof
RU2006134701A (ru) 2004-03-01 2008-04-10 Пептиммьюн Способы и композиции для лечения аутоиммунных заболеваний
CA2558380A1 (en) 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
US7576051B2 (en) 2004-03-11 2009-08-18 Sanyo Chemical Industries, Ltd. Wound dressing for accelerating epidermal regeneration
WO2005092066A2 (en) 2004-03-25 2005-10-06 Janssen Pharmaceutica N.V. Imidazole compounds
US20060194725A1 (en) 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
RU2410115C2 (ru) 2004-05-07 2011-01-27 Пептиммьюн, Инк. Способы лечения заболеваний с помощью статистических сополимеров
ZA200610158B (en) 2004-06-04 2008-07-30 Genentech Inc Method for treating multiple sclerosis
US8053197B2 (en) 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CA2579038A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
KR101317131B1 (ko) 2004-09-09 2013-10-10 테바 파마슈티컬 인더스트리즈 리미티드 정제된 브롬화 수소산을 이용한 폴리펩타이드류의 혼합물의제조방법
WO2006050122A1 (en) 2004-10-29 2006-05-11 Sandoz Ag Processes for preparing glatiramer
WO2006055871A2 (en) 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Treatment for multiple sclerosis
EP1827108B1 (en) 2004-11-29 2015-04-08 Yeda Research And Development Co., Ltd. Induction of neurogenesis and stem cell therapy in combination with copolymer 1
WO2006083608A1 (en) 2005-02-02 2006-08-10 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
CA2596842A1 (en) 2005-02-02 2006-08-10 Yeda Research & Development Co. Ltd Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders
WO2006089066A1 (en) 2005-02-15 2006-08-24 Neuromolecular Pharmaceuticals, Inc. Combinations therapy for treatment of demyelinating conditions
US20080261894A1 (en) 2005-02-17 2008-10-23 Rivka Kreitman Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2606194A1 (en) 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
WO2006127587A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2007021970A2 (en) 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Stable pharmaceutical formulations and methods of use thereof
WO2007030573A2 (en) 2005-09-09 2007-03-15 Yeda Research And Development Co. Ltd. Polypeptides useful for molecular weight determinations
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
WO2007081975A2 (en) 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
WO2007100763A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
EP2676967B1 (en) 2006-02-28 2019-08-14 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
EP2002258B1 (en) 2006-03-15 2017-09-27 The Brigham and Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
CA2650653C (en) 2006-04-28 2016-03-29 Momenta Pharmaceuticals, Inc. Methods of evaluating glatiramer acetate
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
AU2007264682B2 (en) 2006-06-28 2012-09-06 Yeda Research & Development Co. Ltd Method of treatment of age-related macular degeneration
TWI542374B (zh) 2006-06-30 2016-07-21 艾伯維生物技術有限責任公司 自動注射裝置
ATE452140T1 (de) 2006-07-05 2010-01-15 Momenta Pharmaceuticals Inc Verbessertes verfahren zur herstellung von copolymer-1
US20080248122A1 (en) 2006-10-06 2008-10-09 Baxter International Inc. Microencapsules Containing Surface-Modified Microparticles And Methods Of Forming And Using The Same
KR20090095648A (ko) 2006-12-15 2009-09-09 아보트 러보러터리즈 신규한 옥사디아졸 화합물
WO2008075365A1 (en) 2006-12-20 2008-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for treatment of age related degeneration of the retina
EP2139467B1 (en) 2007-02-08 2016-09-21 Biogen MA Inc. Neuroprotection in demyelinating diseases
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
DK2187882T3 (da) 2007-07-11 2013-04-08 Medicinova Inc Behandling af progressiv neurodegenerativ sygdom med ibudilast
US8193147B2 (en) 2007-09-24 2012-06-05 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
CN101808515A (zh) 2007-09-25 2010-08-18 雅培制药有限公司 作为趋化因子受体拮抗剂的八氢并环戊二烯化合物
WO2009042892A1 (en) 2007-09-26 2009-04-02 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009063459A2 (en) 2007-11-13 2009-05-22 Yeda Research And Development Co. Ltd Synthetic peptide copolymers for treatment of neurodevelopmental disorders
US20090149541A1 (en) 2007-11-28 2009-06-11 Yafit Stark Method of delaying the onset of clinically definite multiple sclerosis
ES2329327B1 (es) 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
CA2732228A1 (en) 2008-07-25 2010-01-28 The Johns Hopkins University Methods and compositions for treating and preventing autoimmune diseases
WO2010024908A1 (en) 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis
AR073573A1 (es) 2008-09-10 2010-11-17 Acorda Therapeutics Inc Metodos para utilizar composiciones de aminopiridina de liberacion sostenida
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
EP2355660A4 (en) 2008-10-13 2012-05-02 Biovista Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
BRPI0922871A2 (pt) 2008-12-11 2016-11-16 Biovista Inc metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos
US8802075B2 (en) 2009-02-18 2014-08-12 Eyeon Particle Sciences Llc Bi-functional co-polymer use for opthalmic and other topical and local applications
EP2246048A1 (en) 2009-04-30 2010-11-03 Santhera Pharmaceuticals (Schweiz) AG Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
NZ577731A (en) 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
CA2697570C (en) 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
AU2013203367C1 (en) 2009-08-20 2018-01-18 Yeda Research & Development Co., Ltd Low frequency glatiramer acetate therapy
HUE031282T2 (hu) 2009-08-20 2017-06-28 Yeda Res & Dev Alacsony gyakoriságú glatiramer acetát terápia
EP2490685B1 (en) 2009-10-22 2017-12-13 University College Dublin National University Of Ireland, Dublin Causal therapy of diseases or conditions associated with cns or pns demyelination
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US20110250206A1 (en) 2010-02-11 2011-10-13 Axtell Robert C Markers for determination of patient responsiveness
EP2982371A1 (en) 2010-02-12 2016-02-10 Biogen MA Inc. Dimethyl fumarate with glatiramer acetate or interferon-beta for treating multiple sclerosis
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
KR20130043196A (ko) 2010-07-29 2013-04-29 닥터 레디스 래보러토리즈, 인코포레이티드 글라티라머 아세테이트 분자량 마커
CA2808907A1 (en) 2010-08-20 2012-02-23 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
GB2485169A (en) 2010-11-03 2012-05-09 Univ Jw Goethe Frankfurt Main (R)-flurbiprofen for use in the treatment of multiple sclerosis
EP2500072A1 (en) 2011-03-15 2012-09-19 LEK Pharmaceuticals d.d. A novel process of residual solvent removal
NZ616308A (en) 2011-04-08 2016-03-31 Biogen Ma Inc Biomarkers predictive of therapeutic responsiveness to ifnβ and uses thereof
SG194099A1 (en) 2011-04-15 2013-11-29 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2699317B1 (en) 2011-04-21 2016-08-10 Mapi Pharma Limited Random pentapolymer for treatment of autoimmune diseases
EP3467509B1 (en) 2011-05-04 2025-11-26 Cellular Technology, Ltd Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis
US20140348861A1 (en) 2011-05-05 2014-11-27 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
PT2529757E (pt) 2011-05-31 2014-02-27 Rovi Lab Farmaceut Sa Formulação para implante de paliperidona
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
KR20140148411A (ko) 2012-03-12 2014-12-31 메디뮨 엘엘씨 항-cd19 항체를 이용한 다발성 경화증의 치료
GB201208850D0 (en) 2012-05-18 2012-07-04 Alphaptose Gmbh Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis
US9132138B2 (en) 2012-08-27 2015-09-15 Casi Pharmaceuticals, Inc. Method for the treatment of multiple sclerosis
MX2015004436A (es) 2012-10-09 2015-06-24 Biogen Idec Inc Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
EA201591251A1 (ru) 2013-01-04 2016-05-31 Тева Фармасьютикал Индастриз Лтд. Характеризация лекарственного продукта, родственного ацетату глатирамера
AU2014205529B2 (en) 2013-01-08 2018-08-09 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
HK1218251A1 (zh) 2013-02-15 2017-02-10 Teva Pharmaceutical Industries Ltd. 用拉喹莫德治疗多发性硬化症
EA201591687A1 (ru) 2013-03-12 2016-07-29 Тева Фармасьютикал Индастриз Лтд. Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата
US20160040236A1 (en) 2013-03-15 2016-02-11 Biogen Ma Inc. Systems and methods for characterization of multiple sclerosis
CN103169670B (zh) 2013-03-22 2016-07-06 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
EP3043819A4 (en) 2013-09-11 2017-04-05 Compugen Ltd. Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015140790A1 (en) 2014-03-17 2015-09-24 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
EP3137087B1 (en) 2014-04-28 2023-09-06 The Regents of the University of California Estrogen combination for treatment of multiple sclerosis
WO2016036719A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Estrogen therapy for brain gray matter atrophy and associated disability
US10758496B2 (en) 2014-09-02 2020-09-01 The Regents Of The University Of California Estrogen receptor ligand treatment for neurodegenerative diseases
WO2016040861A1 (en) 2014-09-12 2016-03-17 Biogen Ma Inc. Systems and methods for characterization of multiple sclerosis
WO2016064997A1 (en) 2014-10-22 2016-04-28 The Regents Of The University Of California Compositions and methods for treating fatigue and depression
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
US20160213633A1 (en) 2015-01-28 2016-07-28 Teva Pharmaceutical Industries, Ltd. Method of inducing anti-glatiramer acetate antibody response
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2016160830A1 (en) 2015-03-30 2016-10-06 The Regents Of The University Of California Methods of providing neuroprotective therapy
WO2016160832A1 (en) 2015-03-30 2016-10-06 The Regents Of The University Of California Methods of monitoring estriol therapy
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
AU2017414803B2 (en) 2017-05-15 2025-02-13 Mapi Pharma Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516403A (ja) 2010-01-04 2013-05-13 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
WO2018042423A1 (en) 2016-08-28 2018-03-08 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Clinical Trials NCT02212886，2016年06月01日，Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/history/NCT02212886?V_10=View#StudyPageTop [retrieved on 2021.07.13]
Immunol.Res.，2015年，Vol.63，pp.58-69
Multiple Sclerosis Journal，Vol.21, Supple11，2015年，pp.688 Article EP1320

Also Published As

Publication number Publication date
FI3506921T3 (fi) 2023-07-21
HRP20230738T1 (hr) 2023-10-27
JP2019530648A (ja) 2019-10-24
EP4252849A2 (en) 2023-10-04
AU2017319728B2 (en) 2024-09-05
IL301455B2 (en) 2024-04-01
IL301455B1 (en) 2023-12-01
PT3506921T (pt) 2023-08-07
SMT202300251T1 (it) 2023-09-06
AU2017319728A1 (en) 2019-02-07
HUE071047T2 (hu) 2025-07-28
PL4252849T3 (pl) 2025-04-28
HUE062393T2 (hu) 2023-11-28
RS64445B1 (sr) 2023-09-29
IL264914B1 (en) 2023-04-01
EP3506921A1 (en) 2019-07-10
US12370233B2 (en) 2025-07-29
WO2018042415A1 (en) 2018-03-08
DK3506921T3 (da) 2023-07-31
EP4252849A3 (en) 2023-11-01
LT3506921T (lt) 2023-08-10
EP3506921B1 (en) 2023-05-17
US20210283209A1 (en) 2021-09-16
SMT202500136T1 (it) 2025-05-12
IL264914A (cg-RX-API-DMAC7.html) 2019-04-30
RS66690B1 (sr) 2025-05-30
MX2019002284A (es) 2019-09-04
ES2952044T3 (es) 2023-10-26
ES3023741T3 (en) 2025-06-03
BR112019003594A2 (pt) 2019-05-21
EP4252849B1 (en) 2025-02-19
HRP20250396T1 (hr) 2025-05-23
EP4252849C0 (en) 2025-02-19
IL301455A (en) 2023-05-01
PL3506921T3 (pl) 2023-08-21
SI3506921T1 (sl) 2023-10-30
IL264914B2 (en) 2023-08-01
CA3035147A1 (en) 2018-03-08
EP3506921A4 (en) 2020-05-06
CN109982712A (zh) 2019-07-05

Similar Documents

Publication Publication Date Title
JP7193448B2 (ja) 酢酸グラチラマーを含むデポシステム
JP5916622B2 (ja) グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
US12343371B2 (en) Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate
US8377885B2 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE49251E1 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
HK40005874A (en) Depot systems comprising glatiramer acetate
HK40010052A (en) Glatiramer depot systems for treating progressive forms of multiple sclerosis
HK1245667B (zh) 包含格拉默或其药用盐的储药系统

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221208

R150 Certificate of patent or registration of utility model

Ref document number: 7193448

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250